Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-16-2026-01_58_09-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Regulatory
  • FDA experts endorse Moderna’s mRNA seasonal flu shot
  • Regulatory

FDA experts endorse Moderna’s mRNA seasonal flu shot

Pharmaphorum

A unanimous endorsement from FDA advisors brings Moderna's RNA-based seasonal influenza vaccine a step closer to US approval.

Infectious Disease

Read full story

pharminent June 19, 2026 (Last updated: June 22, 2026)

Pharmaphorum

A unanimous endorsement from FDA advisors brings Moderna’s RNA-based seasonal influenza vaccine a step closer to US approval.

Infectious Disease

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’
Next: Biogen to acquire RayThera for up to $1bn

Related Stories

  • Regulatory

Japan approves Sanofi’s Sarclisa combo for MM treatment

pharminent June 22, 2026
  • Regulatory

Moderna flu vaccine wins unanimous support from FDA panel

pharminent June 18, 2026
  • Regulatory

MSD takes on Pfizer’s Prevnar with new Capvaxive approval

pharminent June 18, 2026

You May Have Missed

  • News

AbbVie to Acquire Apogee Therapeutics for Nearly $11 Billion in Immunology Bet

pharminent June 22, 2026
  • M&A / Deals

AbbVie climbs post-Allergan M&A peak with Apogee buy

pharminent June 22, 2026
  • M&A / Deals

Lilly bets up to $800M for BioArctic’s brain delivery tech

pharminent June 22, 2026
  • Clinical Data

Boehringer advances duo for aggressive cancers into phase 3

pharminent June 22, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.